Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHPS | P49366 | 1/20 | 0.40 |
| ▸ | PDE5A | O76074 | 4/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.37 |
| ▸ | PDE2A | O00408 | 2/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12509854 | 0.87 | PDE5A (0.39) | PDE5APDE10APDE2ALMNAATM | |
| SCHEMBL2200829 | 0.82 | PDE5A (0.45) | DHPSPDE5AHSD11B1LMNAKDM4E | |
| SCHEMBL14461773 | 0.81 | PDE5A (0.38) | PDE5APDE10APDE2ALMNAATM | |
| SCHEMBL2203035 | 0.77 | LMNA (0.45) | LMNAHPGDKDM4EHSD17B10KMT2A | |
| SCHEMBL5256030 | 0.73 | DHPS (0.47) | DHPSPDE10APDE2AHSD11B1LMNA | |
| SCHEMBL2199779 | 0.71 | PDE5A (0.66) | PDE5A | |
| SCHEMBL2193613 | 0.69 | KDM4E (0.35) | PDE10APDE2AHPGDKDM4EHSD17B10 | |
| SCHEMBL31095309 | 0.69 | KDM4E (0.35) | PDE10APDE2AHPGDKDM4EHSD17B10 | |
| SCHEMBL4254483 | 0.69 | DHPS (0.41) | DHPS | |
| SCHEMBL10939995 | 0.68 | NPC1 (0.41) | HSD11B1ATMHPGDHSD17B10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977342-B2 | HCV inhibiting bi-cyclic pyrimidines | TIBOTEC-VIRCO VIROLOGY BVBA (BE) | 2011-07-12 | — | — | US | disclosed |
| US-7977342-B2 | HCV inhibiting bi-cyclic pyrimidines | TIBOTEC-VIRCO VIROLOGY BVBA (BE) | 2011-07-12 | — | — | US | disclosed |
| US-20070155716-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155716-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-07-05 | — | — | US | disclosed |
| EP-1799218-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | Tibotec Pharmaceuticals Ltd. (IE) | 2007-06-27 | — | — | EP | disclosed |
| US-7223766-B2 | Bi-cyclic pyrimidine inhibitors of TGFβ | SCIOS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223766-B2 | Bi-cyclic pyrimidine inhibitors of TGFβ | SCIOS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223766-B2 | Bi-cyclic pyrimidine inhibitors of TGFβ | SCIOS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| WO-2006035061-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2006-04-06 | — | — | WO | disclosed |
| US-20050004143-A1 | Bi-cyclic pyrimidine inhibitors of TGFbeta | SCIOS, INC. | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155716-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | UMPS, NUDT1, PNP | DHPS 83/4885PDE5A 1152/4885PDE10A 1130/4885 |
| US-20050004143-A1 | Bi-cyclic pyrimidine inhibitors of TGFbeta | TYMP, TYMS, TGFBR1 | DHPS 245/4885PDE5A 977/4885PDE10A 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.